http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 03 Sep 2026 08:32:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2421+at+JPMorgan/27022501.html JPMorgan analyst Brian Cheng raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $21.00 (from $14.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2421+at+JPMorgan/27022501.html Thu, 03 Sep 2026 08:32:22 -0400 XNCR http://www.streetinsider.com/Press+Releases/Xencor+to+Present+at+the+2026+Cantor+Global+Healthcare+Conference/27018771.html <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.</p><p>A live webcast of the presentation will be available under “Events &amp; Presentations” in the Investors section of Xencor’s website located at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.xencor.com&amp;esheet=54598158&amp;newsitemid=20260902523892&amp;lan=en-US&amp;anchor=www.xencor.com&amp;index=1&amp;md5=b584dc3831e4f2d59482305c168660da" shape="rect">www.xencor.com</a>. A replay of the event will be available for at least 30 days following the presentation.</p><p><strong>About Xencor</strong></p><p>Xencor is a clinical-stage biopharmaceutical company developing http://www.streetinsider.com/Press+Releases/Xencor+to+Present+at+the+2026+Cantor+Global+Healthcare+Conference/27018771.html Wed, 02 Sep 2026 16:01:00 -0400 XNCR http://www.streetinsider.com/Business+Wire/Xencor+to+Present+at+the+2026+Cantor+Global+Healthcare+Conference/27018771.html <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.</p><p>A live webcast of the presentation will be available under “Events &amp; Presentations” in the Investors section of Xencor’s website located at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.xencor.com&amp;esheet=54598158&amp;newsitemid=20260902523892&amp;lan=en-US&amp;anchor=www.xencor.com&amp;index=1&amp;md5=b584dc3831e4f2d59482305c168660da" shape="rect">www.xencor.com</a>. A replay of the event will be available for at least 30 days following the presentation.</p><p><strong>About Xencor</strong></p><p>Xencor is a clinical-stage biopharmaceutical company developing http://www.streetinsider.com/Business+Wire/Xencor+to+Present+at+the+2026+Cantor+Global+Healthcare+Conference/27018771.html Wed, 02 Sep 2026 16:01:00 -0400 XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2420+at+RBC+Capital/26878206.html RBC Capital analyst Leonid Timashev raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $20.00 (from $19.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2420+at+RBC+Capital/26878206.html Thu, 06 Aug 2026 06:59:15 -0400 XNCR http://www.streetinsider.com/Earnings/Xencor+%28XNCR%29+Tops+Q2+EPS+by+51c/26873698.html <p>Xencor (NASDAQ: XNCR) reported Q2 EPS of ($0.29), $0.51 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $51.22 million versus the consensus estimate of $18.23 million.</p><p>For earnings history and earnings-related data on Xencor (XNCR) <a href="http://www.streetinsider.com/ec_earnings.php?q=XNCR">click here</a>.</p> http://www.streetinsider.com/Earnings/Xencor+%28XNCR%29+Tops+Q2+EPS+by+51c/26873698.html Wed, 05 Aug 2026 16:03:51 -0400 XNCR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xencor+Inc++++++++++++++++For%3A+Jun+30/26873672.html si-local-file:///var/storage/secattach/20260805/26873672.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xencor+Inc++++++++++++++++For%3A+Jun+30/26873672.html Wed, 05 Aug 2026 16:02:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xencor+Inc++++++++++++++++For%3A+Jun+30/26873672.html si-local-file:///var/storage/secattach/20260805/26873672.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xencor+Inc++++++++++++++++For%3A+Jun+30/26873672.html Wed, 05 Aug 2026 16:02:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html <p class="bwalignc"> -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- </p><p class="bwalignc"> -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- </p><p class="bwalignc"> -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended http://www.streetinsider.com/Press+Releases/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html <p class="bwalignc"> -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- </p><p class="bwalignc"> -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- </p><p class="bwalignc"> -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended http://www.streetinsider.com/Press+Releases/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html <p class="bwalignc"> -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- </p><p class="bwalignc"> -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- </p><p class="bwalignc"> -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended http://www.streetinsider.com/Business+Wire/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html <p class="bwalignc"> -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- </p><p class="bwalignc"> -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- </p><p class="bwalignc"> -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended http://www.streetinsider.com/Business+Wire/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR